Option chain shows key data for Phio Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Phio Pharma.

Phio Pharma (NASDAQ:PHIO) Stock, Option Chain

Phio Pharma

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

wall street christmas unsplash

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

AIFF

HEES

MBIO

NMHI

PHIO

Dow Gains Over 200 Points; Signet Jewelers Shares Plunge

Crude-oil-4-logo

Intraday Update

Crude Oil Down 1%; Firefly Neuroscience Shares Spike Higher

PHIO copy

Movers

General

Phio Pharmaceuticals stock drops 39.1% after announcing a $3.19 million direct offering and concurrent private placement.





What&#39;s Going On With Phio Pharmaceuticals Stock Today?

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharmaceuticals Corp

Press Releases

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Power Nickel (TSXV: PNPN) (OTCQB: PNPNF) CEO Unveils Game-Changing Developments in New Video – More Inside Watch Now!

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

DATS

KAVL

PNPNF

PRSO

TSXV:PNPN

Aditxt

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Azitra

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

GT Biopharma

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Oragenics

Organovo Holdings

Portage Biotech

Plus Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sunshine Biopharma

SILO Pharma

Soligenix

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

HC Wainwright & Co.

Phio Pharmaceuticals

Comments

Phio Pharma

Phio Pharma (PHIO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga